Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.

Informazioni relative al progetto

WoundRinse

ID dell’accordo di sovvenzione: 816119

DOI

10.3030/816119

Progetto chiuso

Data della firma CE 9 Maggio 2018

Data di avvio 1 Giugno 2018

Data di completamento 30 Novembre 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

SOFTOX SOLUTIONS AS
Norway

Periodic Reporting for period 1 - WoundRinse (Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.)

Periodo di rendicontazione: 2018-06-01 al 2018-11-30

Sintesi del contesto e degli obiettivi generali del progetto

SoftOx Solutions AS is in the process of developing an antimicrobial solution for treatment of infection on tissue. With the solution’s unique effect, the company aims to replace the use of antibiotics with the use of the Company’s topical applications. SoftOx’ antimicrobial solutions are efficient towards biofilm embedded and planktonic bacteria, virus, spores and fungi. The antimicrobial solution has been tested for potential resistance-issues, and it has not been observed inducement of resistance. The company’s first product line includes both medical devices and drugs, fighting chronic and antimicrobial resistant infections in acute and chronic wounds.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Biocompatibility tests according to ISO guidelines, including relevant animal models, show that SoftOx antimicrobials are well tolerated and do not impede natural wound healing. Also, an animal study on horse legs showed significant reduction in bacterial burden, thus documenting effect in vivo. Hygiene hand-rub test of studies of 18 healthy volunteers’ (EN 1500) showed a Log 4 reduction of the E coli bacteria within 1 minute, demonstrating significant effect as a hand-disinfectant.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The challenges targeted are some of the major issues for modern medicine, namely antibiotic resistance, biofilm infections in chronic wounds and hospital acquired infections. The O’Neill Report estimates a cost of up to USD 100 trillion and 10 million deaths yearly if there is no new alternative to the present antibiotic within 2050. Chronic wounds with biofilm infections are estimated to affect as much as 40 million patients yearly (leading to two million amputations) worldwide with a treatment cost of USD 260 billion.
Hospital acquired infections affects between 7 - 12 percent of hospitalized patients and have become a major source for spreading antibiotic-resistant bacteria. Products derived from the SoftOx technology has proven during the project to have the potential to become effective tools to help combat several of these challenges and threats to human health.

Company Logo